Agonists and antagonists of mineralocorticoids. The relation between structure and activity
Fagart, J.; Pinon, G.M.; Rafestin-Oblin, M.E.
Annales de Cardiologie et D'angeiologie 53(3): 154-157
2004
ISSN/ISBN: 0003-3928 PMID: 15291173 Document Number: 582802
The mechanism of action of aldosterone and its links with the mineralocorticoids receptor (MR) are described. The physiologic importance of the MR structure is emphasized, in relation with the preferential activation of the receptor by aldosterone.
Document emailed within 1 workday
Related Documents
Hough, L.B.; Nalwalk, J.W.; Li, B.Y.; Leurs, R.; Menge, W.M.; Timmerman, H.; Carlile, M.E.; Cioffi, C.; Wentland, M. 1997: Novel qualitative structure-activity relationships for the antinociceptive actions of H2 antagonists, H3 antagonists and derivatives Journal of Pharmacology and Experimental Therapeutics 283(3): 1534-1543Bumpus, F.M. 1977: Mechanisms and sites of action of newer angiotensin agonists and antagonists in terms of activity and receptor Federation Proceedings 36(8): 2128-2132
Ferry, R.C.; Unsworth, C.D.; Molinoff, P.B. 1993: Effects of agonists, partial agonists, and antagonists on the regulation of 5-hydroxytryptamine2 receptors in P11 cells Molecular Pharmacology 43(5): 726-733
Slepushkin, V.D.; Grössler, J.; Kuhne, H.; Scheuch, D.W. 1992: The effect of agonists and antagonists of opiate receptors on the activity of the kallikrein-kinin system in hemorrhagic shock Anesteziologiia i Reanimatologiia 3: 19-22
Kertscher, H.P. 1997: PAF-antagonists with lipid structure. 6. Alkylpropandiol lipids with acyl- and ether- structures at the C-3 position and heterocyclic head groups; synthesis, characterization and structure-activity relationship Die Pharmazie 52(9): 672-675
Shi, C.Z.; Li, X.M.; Liu, Y.; Zhang, J.T. 1990: Application of mouse tail artery for the study of alpha adrenoceptor agonists and antagonists and calcium antagonists Yao Xue Xue Bao 25(3): 223-226
Ebert, B.; Madsen, U.; Johansen, T.N.; Krogsgaard-Larsen, P. 1991: NMDA receptor agonists: relationships between structure and biological activity Advances in Experimental Medicine and Biology 287: 483-487
Schreiber, R.; Brocco, M.; Audinot, V.; Gobert, A.; Veiga, S.; Millan, M.J. 1995: (1-(2,5-dimethoxy-4 iodophenyl)-2-aminopropane)-induced head-twitches in the rat are mediated by 5-hydroxytryptamine (5-HT) 2A receptors: modulation by novel 5-HT2A/2C antagonists, D1 antagonists and 5-HT1A agonists Journal of Pharmacology and Experimental Therapeutics 273(1): 101-112
Herdewijn, P. 1995: Structure-activity relation study of anti-herpes associations with a 2'-deoxyuridine basic structure Verhandelingen - Koninklijke Academie Voor Geneeskunde van Belgie 57(6): 601-615
Perez, M.; John, G.W. 1999: Structure-activity relationships and pharmacological profiles of new 5-HT(1) receptor agonists as antimigraine agents Current Opinion in Drug Discovery and Development 2(4): 304-310
He, K.Q.; Cheng, G.F.; Xi, F.D.; Guo, Z.R.; Zhu, X.Y. 1996: Structure-activity relationship studies of chalcones as SRS-A receptor antagonists Yao Xue Xue Bao 31(11): 878-880
Belcheva, I.; Stoytchev, T. 1983: Neuropharmacological activity of newly-synthesized derivatives of 3,3-diethyl-2,4-pyridinedione. V. Relation between chemical structure and pharmacological activity Acta Physiologica et Pharmacologica Bulgarica 9(4): 37-47
Elferink, J.G.; Salemink, C.A. 1975: Relation between structure and cholinergic activity. II. Synthesis and muscarinic activity of some sulfur analogs of 2-methyl-4-trimethylammoniomethyl-1,3-dioxolane-iodide Arzneimittel-Forschung 25(11): 1702-1705
Elferink, J.G.; Salemink, C.A. 1975: Relation between structure and muscarinic activity III. Synthesis and cholinergic activity of some-onium compounds related to 2-methyl-4-trimethylammoniomethyl-1,3-dioxolane iodide Arzneimittel-Forschung 25(12): 1858-1860
Kohli, J.D.; Weder, A.B.; Goldberg, L.I.; Ginos, J.Z. 1980: Structure activity relationships of N-substituted dopamine derivatives as agonists of the dopamine vascular and other cardiovascular receptors Journal of Pharmacology and Experimental Therapeutics 213(2): 370-374
Liao, P.-A.; Pan, S.-W.; Chen, C.-Y.; Deng, C.-Y.; Dong, Y.-H. 2023: Prescription Patterns of new use of Fixed-Dose Combination Inhalers in Patients with Chronic Obstructive Pulmonary Disease: Long-Acting β2 Agonists Plus Long-Acting Muscarinic Antagonists versus Long-Acting β2 Agonists Plus Inhaled Corticosteroids International Journal of Chronic Obstructive Pulmonary Disease 18: 553-563
Glennon, R.A. 1990: Do classical hallucinogens act as 5-HT2 agonists or antagonists? Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology 3(5-6): 509-517
Kohli, J.D. 1990: Dopamine receptor agonists and antagonists Proceedings of the Western Pharmacology Society 33: 21-27
Phillips, L.; Benghuzzi, H.; Cason, Z.; Tucci, M. 2005: The effect of agonists and antagonists on Hep-2 cells Biomedical Sciences Instrumentation 41: 135-140
Dyban, A.P.; Tikhodeeva, I.I.; Khromov-Borisov, N.V. 1975: Relation between the teratogenic activity and chemical structure of the molecules of medicinal substances Vestnik Akademii Meditsinskikh Nauk SSSR 12: 78-88